Abstract AB0814 – Table 1. Descriptive data of 7 patients treated with STS

Diagnosis	Age/ gender	Localization	Number of injections	Interval (days)	Dosis (mg)	VAS pre- treatment (mm)	VAS after treatment (mm)	Size pre treatment (mm)	Size after treatment (mm)
DM	33, F	Left leg (medial)	3	15	2	10	0	1.1	1.1
		Left leg (posterior)	3		2			0.8	0.6
Limited SSc	67, F	Hand dystal phalanx	2	15	5	80	60	1.6	1.4
		Elbow	2		12			1.2	1.2
Limited SSc	55, F	Elbow	3	15	10	0	0	2.5	2.5
		Leg	3		20			2.3	2.3
Limited SSc	67, F	Hand dystal phalanx	8	15	9.1	50	20	1.6	1.7
Diffuse SSc	52, F	Ear	2	23	7.6	70	20	0.5	0.5
Diffuse SSc	56, F	Hand dystal phalanx	4	12	7.5	60	60	2.5	2.3
Diffuse SSc	62, M	Elbow	3	30	17.5	0	0	13.	13.21
Mean±Sd	56±10.14	-	3.3±1.67	17.85±5.86	9.27±5.66	38.75±31.81	22.85±24.90	2.73±3.55	2.70±3.62

*DM=dermatomyositis and SSc=systemic sclerosis; Sd=standart deviation

AB0815 HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC SCLEROSIS TREATED WITH TWO DIFFERENT INTRAVENOUS ILOPROST REGIMENS

T. Schioppo¹, L. Scalone^{2,3}, P. Cozzolino², L. Mantovani^{2,3}, G. Cesana², O. De Lucia¹, A. Murgo¹, F. Ingegneri^{1,4}. ¹Rheumatology, Pini, Milan; ²CESP, University of Milan Bicocca, Monza; ³Fondazione CHARTA; ⁴University of Milan, Milan, Italy

Background: In systemic sclerosis (SSc), Raynaud's phenomenon (RP) and digital ulcers (DU) can decrease health related quality of life (HRQoL). Intravenous (IV) iloprost (ILO) is administered for RP, after oral therapy failure, and DU healing. HRQoL is considered fundamental to assess the impact of the disease and therapy on patients: EQ-5D-5L has been satisfactory used to assess the general HRQoL in SSc.

Objectives: Aim of our study was to estimate HRQoL in SSc patients treated with two different IV ILO regimens and in patients not requiring IV ILO.

Methods: This was a monocentric, prospective, pragmatic and non-randomised study. Enrolled SSc patients were divided into 3 groups: no IV ILO (group A), IV ILO once monthly (B) or IV ILO for 5 consecutive days every 3 months (C). HRQoL was assessed using EQ-5D-5L through a telephone interview. Group A patients were evaluated at baseline and after 3 months; group B 2 days before each infusion and 2 weeks after each infusion; group C 2 days before each therapy cycle, and after 2 and 6 weeks after the first cycle of therapy. The EQ-5D-5L describes HRQoL, measures the overall health state with a 0–100 visual analogue scale (VAS) and values health with a utility index. Multiple regression analyses was performed to calculate VAS and mean utility index in each group (confounders: age, sex, treatment group, baseline utility or VAS score, average outdoor temperature the week before the evaluation at patient's place of residence, RP VAS, disease duration and modified Rodnan skin score).

Results: 96 patients were enrolled: 52 in group A, 24 in B, and 20 in C. Of these 35, 21 and 16 completed the study respectively. Utility and VAS score at the end

of the three months, as adjusted for the possible confounders, were not statistically different in the three groups.

Conclusions: Utility and VAS, at 3 months follow-up, were not different in the 3 groups as if IV ILO was able to make patients requiring IV ILO as similar as patients not requiring IV ILO. Moreover, in this model there was no difference between the two ILO regimens (1 days monthly vs 5 every 3 months). These results suggest that our therapeutic approach, based on various criteria such as demographic, clinical characteristics, logistic aspects and patients' preferences, allows to reach or to maintain HRQoL at comparable levels between the three groups considered.

Acknowledgements: Meteo Operations Italia Srl – Centro Epson Meteo for temperature data.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.2061

AB0817 PROMINENT NAILFOLD CAPILLARY AVASCULAR AREA PREDICTS MALIGNANCY IN PROGRESSIVE SYSTEMIC SCLEROSIS

W.-N. Huang^{1,2}, Y.-M. Chen^{1,2,3}, W.-T. Hung¹, C.-W. Hsieh¹, C.-T. Lin¹, Y.-H. Chen^{1,2}. ¹Allergy, Immunology And Rheumatology, Taichung Veterans General Hospital, Taichung; ²Faculty of Medicine, National Yang Ming University, Taipei; ³Institute of Biomedical Science, National Chung Hsing University, Taichung, Taiwan, Province of China

Background: Systemic sclerosis (SSc) is an autoimmune disease characterised with proximal scleroderma and internal organ involvement. Observational studies demonstrated increased incidences of cancer in SSc patients¹. Nailfold capillaroscopy is useful for the diagnosis and disease activity assessment of SSc.

Abstract AB0815 – Table 1

Independent variable description	Utility				VAS			
	Coefficient	P	95% CI		Coefficient	P	95% CI	
Age (years)	-0.001	0149	-0.002	0000	-0.332	0026	-0.623	-0.041
Sex								
Female (reference)	-	-	-	-	-	-	-	-
Male	0028	0148	-0.010	0067	3637	0521	-7.618	14 891
Treatment group								
ILO monthly (reference)	-	-	-	-	-	-	-	-
ILO for 5 days every 3 months	0001	0975	-0.037	0038	7252	0182	-3.486	17 990
No ILO	-0.005	0771	-0.037	0028	9160	0005	-0.185	18 505
Utility at baseline	0731	0000	0526	0936	0270	0012	0061	0478
Average temperature	0003	0155	-0.001	0007	0219	0714	-0.971	1409
RP VAS	-0.005	0054	-0.010	0000	-1.114	0131	-2.569	0341
Disease duration	0001	0534	-0.001	0002	0172	0510	-0.348	0693
Skin score (mRSS)	-0.003	0021	-0.006	-0.001	-0.161	0695	-0.977	0655
Constant	0241	0025	0032	0451	68 969	0000	37 504	100.43